The incidence of pertussis in children in low-and middleincome countries is poorly described. This study aimed to prospectively investigate the incidence of pertussis in South African children hospitalized with lower respiratory tract infection (LRTI). Methods: Children hospitalized with LRTI in Cape Town, South Africa were enrolled over 1 year. Clinical data were collected. A nasopharyngeal (NP) swab and induced sputum (IS) were taken, and polymerase chain reaction specific for Bordetella pertussis (IS481+/hIS1001−) and Bordetella parapertussis (IS1001+) was performed. Results: A total of 460 children with median age 8 [interquartile range (IQR), 4-18] months were studied. B. pertussis was detected in 17 (3.7%) while total Bordetella spp. were identified on 23 (5.0 %) of 460 NP. Adding IS testing increased the identification of B. pertussis to 32 of 460 cases (7.0%; 95% confidence interval, 4.8%-9.7%); P = 0.028 and total Bordetella to 41 of 460 (8.9%; 95% confidence interval, 4-10%); P = 0.020. Shorter duration of symptoms [median 2 (IQR, 2-3) days versus 5 (IQR, 3-7) days; P = 0.0008] was associated with detection of B. pertussis on IS versus NP. B. pertussis was detected in 15.8% (n=3/19) of HIV-infected children, 10.9% (n = 10/92) of HIV exposed uninfected and 5.4% (n = 19/349) of HIV-unexposed uninfected children. Risk of B. pertussis decreased with each additional dose of diphtheria, tetanus and acellular pertussis vaccine [0 doses = 17.9%; 1 dose = 7.0%; 2 doses = 6.9%; and >3 doses = 6.2%]. Conclusions: Pertussis is common in South African children hospitalized with LRTI particularly if HIV exposed or infected but decreases sequentially with vaccination doses. Polymerase chain reaction on IS specimen provides confirmation earlier than NP while increasing overall diagnostic yield.
P
ertussis is an important cause of severe respiratory disease in children globally. Most cases are because of Bordetella pertussis infection with a small percentage attributed to Bordetella parapertussis. 1 The World Health Organization (WHO) estimates that between 20 and 40 million cases of pertussis and 300,000 pertussis-related deaths occur around the world each year, 90% of which occur in children in low-and middle-income countries (LMICs). 2, 3 Data are largely unavailable in LMICs, making it difficult to assess the true burden of disease and the impact of vaccination. 4, 5 Pertussis can be difficult to diagnose clinically, especially in infants. 6 Polymerase chain reaction (PCR), commonly performed on a nasopharyngeal (NP) specimen obtained by swab or aspiration, has greatly improved the ability to confirm cases. [7] [8] [9] [10] Because of lack of resources for laboratory confirmation in most LMICs, diagnosis is largely made on clinical grounds utilizing clinical case definitions, such as the one recommended by WHO. 5, 11, 12 Since 2009, South Africa has introduced an acellular vaccine in a combination formulation with 4 other vaccines (DTaP-IPV/HIB; Pentaxim ™ , Sanofi Pasteur, Lyon, France). 13 Available data indicate that coverage for the pertussis vaccine in the Western Cape Province, where this study was done, declines from 6 weeks with each extra dose in the schedule, given at 10 weeks, 14 weeks, and 18 months. 14 This study aimed to prospectively investigate the incidence and risk factors for pertussis in South African children hospitalized with lower respiratory tract infection (LRTI).
Materials and Methods
A prospective study of the incidence and risk factors for pertussis was performed in children hospitalized with LRTI.
Participants
Sequential children admitted to Red Cross War Memorial Children's Hospital, Cape Town, South Africa, from September 7, 2012 to September 6, 2013 for LRTI were eligible for enrollment. Inclusion criteria were WHO-defined age-specific tachypnoea or lower chest indrawing, apnea, age less than 13 years, informed parental consent and enrolment within 48 hours of admission. Participants were excluded if they had a previous admission to a healthcare facility in the preceding 2 weeks. A maximum of 4 children were enrolled per working day to ensure distribution of enrollment throughout the year. The attending doctors at Red Cross War Memorial Children's Hospital provided clinical care. Children were followed up until they were discharged from hospital.
A detailed history and clinical examination were done, especially noting the presence of cough, apnea, duration of symptoms and use of antibiotics before admission. History of HIV exposure, infection and where relevant, antiretroviral treatment, were recorded. Information on immunization was abstracted from the Road to Health Card, a standardized national record for each child, and the date and type of each vaccine recorded. Vaccination status was regarded as a completed primary schedule if ≥3 doses were received. The status was classified unknown where Road to Health Card was missing and up to date for age if an appropriate number of doses for the child's age were received.
HIV screening was done using an enzyme-linked immunosorbent assay (ELISA) test (Architect HIV Ag/Ab Combo, Abbott Diagnostics, Wiesbaden, Germany). Children younger than with an HIV PCR test (COBAS AmpliPrep/COBAS Taqman HIV-1, Roche Molecular Diagnostics, Pleasanton, CA), whereas those older than 18 months had a second ELISA test (Enzygnost Anti-HIV 1/2 Plus, Siemens/Dade Behring, Erlangen, Germany). HIV infection was defined as a positive PCR in children younger than 18 months or 2 positive ELISA tests in older children. Children younger than 18 months who were ELISA positive but PCR negative were classified as HIV exposed uninfected; older children were classified as HIV exposed uninfected if the mother was HIV infected at the time of the pregnancy but the child tested HIV negative.
Two NP swabs followed by an induced sputum (IS) specimen were collected from each child. The first NP specimen was taken using a cotton wool tipped swab and immediately put into a gel Amies transport medium and sent to the laboratory for culture. The second NP specimen was taken with a nylon flocked swab (FLOQSwabs, Copan Diagnostics, Murrieta, CA) and immediately transferred into a nucleic acid preservation medium (PrimeStore, Longhorn Vaccines & Diagnostics, San Antonio, TX). The IS specimen was collected after nebulization with a bronchodilator and hypertonic saline as previously described. 15 Both specimens were frozen at minus 80°C until thawed for batched molecular diagnostic testing.
The Amies swab was inoculated onto a charcoal-enriched culture medium (Greenpoint Media Laboratory, National Health Laboratory Service, Cape Town, South Africa) and incubated for a minimum of 7 days. If growth was detected, the bacterial colonies were tested by PCR as described below.
PCR specific for insertion sequences IS481 for Bordetella spp. and IS1001 for B. parapertussis was done with a validated commercial kit (LightMix Kit B. pertussis and B. parapertussis, TIB MolBiol, Berlin, Germany) using previously published primers. 16 To exclude Bordetella holmesii (IS481+, IS1001−, hIS1001+) before the diagnosis of B. pertussis infection was made, all specimens testing positive for IS481 were tested for the presence of insertion site hIS1001.
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Controls
Controls were children without symptoms or signs of respiratory illness presenting for other reasons to the same hospital or a nearby primary healthcare facility. Controls were matched to within 12 weeks of birth and 12 weeks of specimen collection of the cases testing positive for Bordetella spp. on the NP specimen. An average of 3 controls was matched to each case. One nylon flocked NP specimen was collected from each control and processed as described above. 
sample size and statistical analysis
A sample size of between 400 and 500 participants was targeted to give a 95% confidence interval (CI) within 3% above and below our estimated prevalence of 5%. Percentages with 95% CI were used to depict proportions of categorical variables, whereas medians with interquartile ranges (IQR) were used to summarize all continuous variables.
Cumulative frequencies of confirmed B. pertussis were described and stratified by age category, HIV status and vaccination status.
A χ 2 or Fisher exact test was used to assess the strength of association between 2 categorical variables as appropriate. The Mann-Whitney U test was used to test the hypothesis of similarity between 2 groups with respect to a continuous variable. A 2-tailed cut-off level of significance at P < 0.05 was used in all hypothesis testing. All analyses were done using Stata Statistical Software Release 13 (StataCorp LP, College Station, TX).
results study Participants
Over the study period, 7792 children were hospitalized of whom 987 children had respiratory illness. Of these, 460 (46.6%) eligible participants were enrolled. The median age was 8 (IQR, 4-18) months and 258 (56.1%) were male. Most children were HIV unexposed uninfected (n=349; 75.9%), whereas 92 (20.0%) were HIV exposed uninfected and 19 (4.1%) were HIV infected, Table 1 . Among HIV-infected children, 1 was WHO HIV stage 1 and 1 HIV stage 2, whereas 10 were stage 3 and 7 were stage 4. Nine (47.4%) HIV-infected children were on antiretroviral treatment of whom 4 had attained viral suppression.
Immunization status was unknown in 9 children. Of 451 (98.0%) with immunization records, 369 (85.2%) were up to date with pertussis vaccine doses for age, whereas 308 (68.3%) had completed the primary schedule. This did not differ by HIV status with 237 of 345 (68.7%) in unexposed uninfected, 59 of 89 (66.3%) in exposed uninfected and 12 of 17 (70.6%) in HIVinfected children, respectively, completing the primary schedule; P = 0.891.
Antibiotics were received by 173 (37.6%) children for a median duration of 1 day (IQR, 1-1 days) before admission. Ceftriaxone (n=99; 57.2 %) and penicillin (n=77; 44.5 %) were the commonest antibiotics received. Seven children received both ceftriaxone and penicillin, whereas 1 child received both ceftriaxone and co-trimoxazole.
Cough (median duration 3; IQR, 2-5 days) and fever were the commonest presenting symptoms (Table 1) . Apnea was reported in 20 (4.4%) participants with a median age of 6 (IQR, 3-16) months, whereas those without apnea had median age of 8 (IQR, 4-18) months; P = 0.26.
description of Microbiologic Confirmation
Both NP and IS specimen collection were well tolerated and obtained in most children with no severe adverse reaction noted in any participant. NP specimens were obtained in all children. In 4 participants, IS could not be obtained as children were transferred or discharged before the specimen could be collected. In all other children (n = 456; 99.1 %), IS was successfully obtained. Two IS specimens were lost because of container leakage.
PCR for IS481 was positive in 17 of 460 NP specimens (3.7 %; 95% CI, 2.2%-5.9%), whereas 7 (1.5%; 95% CI, 0.6%-3.2%) were positive for IS1001. PCR was positive for both targets in 1 participant. Therefore, 23 (5%; 95% CI, 3.2%-7.4%) NP specimens were positive for either target. Of the 454 IS specimens processed, 25 (5.5%; 95% CI, 3.6%-8.0%) were positive for insertion site IS481 and 5 (1.1%; 95% CI, 0.4%-2.5%) positive for IS1001, giving a total of 30 (6.6%; 95% CI, 4.5%-9.3%) IS specimens positive for either Bordetella target.
NP specimens from 4 participants showed bacterial growth compatible with Bordetella spp. on culture but only one was positive on PCR for the IS481 locus. The same participant was also positive for IS481 on the flocked-swab NP specimen. NP specimens from all 70 controls (Table 1) were PCR negative for both IS481 and IS1001 insertion sites.
None of the IS481-positive specimens were positive for the hIS1001 B. holmesii locus and so all were classified as B. pertussis positive, whereas all the IS1001-positive specimens were classified as B. parapertussis positive. In total, 32 (7.0%; 95% CI, 4.8%-9.7%) participants were B. pertussis positive and 11 (2.4%; 95% CI, 1.2%-4.2%) were B. parapertussis positive from NP and IS specimens. Two participants were positive for both organisms. This gave an incidence of 8.9% (95% CI, 6.5%-11.9%; n = 41/460) for either organism. The occurrence of Bordetella cases did not show any seasonal pattern, although enrolled LRTI cases peaked in the autumn and winter season between March and July 2013, Fig. 1 .
Children with confirmed B. pertussis had a median age of 8 months (IQR, 2-21), similar to those without confirmed infection Risk of B. pertussis infection declined with each additional dose of the vaccine received. The highest risk was seen in children who had not received any vaccine with 5 of 28 (17.9%) having confirmed B. pertussis. The risk was 4 of 54 (7.0%), 4 of 58 (6.9%) and 19 of 308 (6.2%) for children that received 1, 2 and ≥3 doses, respectively (Table 2 ). Stratified B. parapertussis incidences were difficult to interpret because of small number of cases (Table 2 ).
use of is Versus nP specimen for diagnostic Confirmation
Ten participants had a positive PCR for IS481 on both NP and IS. In 1 participant, PCR for IS1001 was positive on both the NP and the IS, whereas in another IS1001 was positive on NP and IS481 positive on IS. The latter was counted as a single case of B. pertussis. In total, 30 of 41 (73.2%) Bordetella confirmed cases were detected on IS, whereas only 23of 41 (56.1%) were detected on NP. 
outcome
Only 4 of 41 (9.8%) of confirmed cases were clinically diagnosed as pertussis. The other cases were diagnosed as lobar or bronchopneumonia (n = 15; 36.6%), bronchiolitis (n = 15; 36.6%) or other LRTI (n = 7; 17.1%).
All participants were discharged from hospital with no inhospital deaths occurring. Fourteen (3.0%) children were admitted to a High Dependency or Pediatric Intensive Care Units. Among these, 3 of 41 (7.3%) were Bordetella infected compared with 11 of 419 (2.6%) in the uninfected group; P = 0.120).
The 
disCussion
This study has shown that pertussis is common in South African children hospitalized with LRTI with an estimated 9% having laboratory confirmed infection. B. pertussis was responsible for 75% of the cases with B. parapertussis contributing the rest. These likely represent true cases of pertussis, as they had both clinical and microbiological evidence of disease while all results obtained from controls were negative. The rate is equivalent to 526 cases of laboratory confirmed pertussis for every 100,000 children hospitalized and 4154 of 100,000 children specifically hospitalized with LRTI. The lack of data on the baseline population from which the cases originated made it difficult to estimate the true population incidence. Data from high-income countries report hospitalization incidences of between 2 and 240 per 100,000 population. [18] [19] [20] Possible reasons for the high incidence of disease in our study population include incomplete primary vaccination and a high burden of HIV, which may reduce protection against pertussis. 21 Pertussis cases occurred consistently throughout the year. The proportion of confirmed pertussis cases did not show any seasonal pattern, although there was an overall increase in the number of respiratory cases recruited over the autumn and winter months. This seasonal increase in enrollment reflects a trend we have consistently observed; a prospective birth cohort study done around the same period in the same province of South Africa reported a similar pattern for LRTI. 22 A recent study found the prevalence of pertussis to be <1% in children hospitalized with bronchiolitis over the winter period; however, differences in both diagnostic and sampling methodology made it difficult to compare this finding with this study. 23 HIV-exposed and infected children showed higher risks for pertussis. This is of particular importance in this region with a high burden of maternal HIV with associated intrauterine exposure and infection. 24 The observed increase in pertussis cases in these groups may relate to both reduced vaccine effectiveness and passive immunity associated with HIV infection or exposure. [25] [26] [27] [28] Consistent with other studies, the risk of B. pertussis was higher in younger infants and decreased with each extra dose of vaccine received, with the lowest risk after a completed primary schedule. 18 A novel, important finding was the higher sensitivity for diagnosis of Bordetella spp. on IS specimens, with more confirmed cases on IS compared with NP specimens. The use of NP specimen on its own would have missed 47% of B. pertussis cases compared with 22% missed by IS. When used in addition to the traditional NP specimen, IS significantly increased the yield by 47%. IS was successfully obtained in almost all children and was well tolerated even in very young infants. Large studies of children with suspected pulmonary TB have reported excellent safety, tolerability and good diagnostic yield of IS, even in infants. 15, 29 Our data add to the increasing evidence of the utility and safety of IS for diagnostic confirmation of the etiology of LRTI in young children.
This study also found that testing of IS is more likely to be positive early in the course of disease. Early diagnosis allows for targeted antibiotic therapy, which may reduce severity of illness and allow early prophylaxis for close contacts. 30, 31 The findings of this study suggest that IS should be the recommended specimen for testing children with suspected pertussis either on its own or in addition to NP specimen, rather than the current recommended practice of using NP specimen on its own. 9, 10 Confirming previous studies, culture had very low sensitivity, suggesting that although this method of diagnosis offers opportunity for antibiotic sensitivity testing, it is ineffective for diagnosis. 5 Limitations of this study include lack of detection of other pathogens. The finding of Bordetella infection does not preclude the possibility of co-infections that may have modified the disease presentation. [32] [33] [34] As only hospitalized cases were included in the study, the findings may not be generalizable to children with less severe forms of illness. The small number of confirmed cases limits the interpretation of stratified B. parapertussis incidence. Further studies to investigate these aspects are needed.
As our study demonstrates, the difficulty in diagnosing atypical pertussis may substantially underestimate its role in severe LRTI. Accurate diagnosis is important for timely treatment, institution of infection control measures and assessment of vaccine effectiveness. 5 Macrolides may shorten the duration of symptoms and reduce the very high secondary attack rate associated with B. pertussis. 30, 31 Although there is some concern of rapid emergence of resistance to macrolide antibiotics, empiric use should be considered in young African infants and HIV exposed or infected children hospitalized with LRTI, particularly where pertussis immunization is incomplete. 35 
